Impact Therapeutics of Nanjing will collaborate with Toronto 's Cyclia. using Cyclia's Ligand Express data-based platform to assess the "targetivity" of their novel oncology candidates. Impact said the insights gained from the partnership will improve and validate its assets, which are based on synthetic lethality. The company has developed a portfolio of DNA damage response candidates using its in-house discovery work and is expanding to other novel targets. Impact's lead drug is a clinical stage PARP inhibitor that it has partnered with Shanghai 's Junshi Biopharma. More details.... Stock Symbol: (HK: 1877; SHA: 688180)